186 related articles for article (PubMed ID: 27742386)
1. The Bad and the Good News on Cancer Immunotherapy: Implications for Organ Transplant Recipients.
Maggiore U; Pascual J
Adv Chronic Kidney Dis; 2016 Sep; 23(5):312-316. PubMed ID: 27742386
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
Herz S; Höfer T; Papapanagiotou M; Leyh JC; Meyenburg S; Schadendorf D; Ugurel S; Roesch A; Livingstone E; Schilling B; Franklin C
Eur J Cancer; 2016 Nov; 67():66-72. PubMed ID: 27614165
[TBL] [Abstract][Full Text] [Related]
3. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature.
Abdel-Wahab N; Safa H; Abudayyeh A; Johnson DH; Trinh VA; Zobniw CM; Lin H; Wong MK; Abdelrahim M; Gaber AO; Suarez-Almazor ME; Diab A
J Immunother Cancer; 2019 Apr; 7(1):106. PubMed ID: 30992053
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients?
Maggiore U; Palmisano A; Buti S; Claire Giudice G; Cattaneo D; Giuliani N; Fiaccadori E; Gandolfini I; Cravedi P
Transpl Int; 2021 Dec; 34(12):2442-2458. PubMed ID: 34555228
[TBL] [Abstract][Full Text] [Related]
6. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors.
Perbos E; Juinier E; Guidicelli G; Dromer C; Merville P; Billes MA; Taupin JL; Neau-Cransac M
Clin Transplant; 2014 Sep; 28(9):1054-60. PubMed ID: 25040585
[TBL] [Abstract][Full Text] [Related]
7. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
8. Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients.
Smedman TM; Line PD; Guren TK; Dueland S
Acta Oncol; 2018 Oct; 57(10):1414-1418. PubMed ID: 29912605
[No Abstract] [Full Text] [Related]
9. Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review.
Nguyen LS; Ortuno S; Lebrun-Vignes B; Johnson DB; Moslehi JJ; Hertig A; Salem JE
Eur J Cancer; 2021 May; 148():36-47. PubMed ID: 33721705
[TBL] [Abstract][Full Text] [Related]
10. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
Jaber JJ; Feustel PJ; Elbahloul O; Conti AD; Gallichio MH; Conti DJ
Clin Transplant; 2007; 21(1):101-9. PubMed ID: 17302598
[TBL] [Abstract][Full Text] [Related]
11. Poor Outcomes With the Use of Checkpoint Inhibitors in Kidney Transplant Recipients.
Venkatachalam K; Malone AF; Heady B; Santos RD; Alhamad T
Transplantation; 2020 May; 104(5):1041-1047. PubMed ID: 31415036
[TBL] [Abstract][Full Text] [Related]
12. A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma.
Tsung I; Worden FP; Fontana RJ
Oncologist; 2021 Feb; 26(2):133-138. PubMed ID: 32969143
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.
Chae YK; Galvez C; Anker JF; Iams WT; Bhave M
Cancer Treat Rev; 2018 Feb; 63():116-121. PubMed ID: 29276997
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue.
Aguirre LE; Guzman ME; Lopes G; Hurley J
Oncologist; 2019 Mar; 24(3):394-401. PubMed ID: 30413665
[TBL] [Abstract][Full Text] [Related]
15. Acute rejection features in dual kidney transplant recipients from elderly donors: comparison of calcineurin inhibitor-based and calcineurin inhibitor-free immunosuppressive protocols.
Aiello FB; Furian L; Marino S; Marchini F; Cardillo M; De Fazio N; Rigotti P; Valente M
Int J Immunopathol Pharmacol; 2009; 22(4):1001-7. PubMed ID: 20074463
[TBL] [Abstract][Full Text] [Related]
16. Costimulatory Blockade and Use of Mammalian Target of Rapamycin Inhibitors: Avoiding Injury Part 1.
Augustine J; Hricik DE
Adv Chronic Kidney Dis; 2016 Sep; 23(5):301-305. PubMed ID: 27742384
[TBL] [Abstract][Full Text] [Related]
17. Programmed Cell Death 1 (PD-1) Inhibitors in Renal Transplant Patients with Advanced Cancer: A Double-Edged Sword?
Lai HC; Lin JF; Hwang TIS; Liu YF; Yang AH; Wu CK
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31058839
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review.
Fisher J; Zeitouni N; Fan W; Samie FH
J Am Acad Dermatol; 2020 Jun; 82(6):1490-1500. PubMed ID: 31302190
[TBL] [Abstract][Full Text] [Related]
19. Everolimus: preventing organ rejection in adult kidney transplant recipients.
Dantal J
Expert Opin Pharmacother; 2012 Apr; 13(5):767-78. PubMed ID: 22404500
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: A systematic review.
d'Izarny-Gargas T; Durrbach A; Zaidan M
Am J Transplant; 2020 Sep; 20(9):2457-2465. PubMed ID: 32027461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
